Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1995-05-25
1998-02-10
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
5142355, 5142362, A61K 31675, A61K 31535
Patent
active
057169420
ABSTRACT:
Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
REFERENCES:
patent: 2943022 (1960-06-01), Siemer et al.
patent: 3005818 (1961-10-01), Siemer et al.
patent: 3458509 (1969-07-01), Levine et al.
patent: 3506673 (1970-04-01), Warawa et al.
patent: 3541090 (1970-11-01), Herlinger et al.
patent: 4010266 (1977-03-01), McLoughlin et al.
patent: 4360519 (1982-11-01), White et al.
patent: 4435395 (1984-03-01), Loev et al.
patent: 4505912 (1985-03-01), Kummer et al.
patent: 4705553 (1987-11-01), Buschmann et al.
patent: 4782054 (1988-11-01), Regnier et al.
patent: 4943578 (1990-07-01), Naylor et al.
patent: 5026702 (1991-06-01), Reiffen et al.
patent: 5064838 (1991-11-01), Carr et al.
patent: 5070090 (1991-12-01), Stokbroekx et al.
patent: 5095021 (1992-03-01), Zipplies et al.
patent: 5512570 (1996-04-01), Dorn et al.
Siemer, et al., "Analgesic 1-phenyl-2,3 dimethyl-4-morpholinomethyl-3-pyrazolin-5-ones", Chem. Abstracts, 56, (6), p. 5977 (1962).
Sinkula, et al., "Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs", J. Pharm. Sciences, 64 (2), pp. 181-210 (1975).
Svensson, "Prodrugs: metabolism-based drug design" Pharmaceutisch Weekblad, 122, pp. 245-250, (1987).
Advenier, et al., "Neurokinin A (NK2) Receptor Revisited with SR 48968 . . . ", Biochem. and Biophys. Res. Comm., 184(3), pp. 1418-1424 (1992).
Balant, et al., "Prodrugs for the improvement of drug absorption via different routes of administration.", Eur. J. Drug Metab. Pharmaco., 15(2), pp. 143-153, (1990).
Bodar, et al., "Novel Approaches in Prodrug Design", Drugs Future, VI(3), pp. 165-182 (1981).
Bundgaard, "The double prodrug concept and its applications", Adv. Drug Delivey Rev., 3 pp. 39-65, (1989).
Edmonds-Alt, et al., "A Potent and Selective Non-Peptide Antagonist of the Neurokinin A (NK2) Receptor", Life Sciences., 50, pp. PL101-PL106 (1992).
Frossard, et al., "Tachykinin Receptors and the Airways", Life Sciences., 49, pp. 1941-1953 (1991).
Guthrie, et al., "The Use of Periodate-oxidised Glycosides in the Robinson-Schopf . . . ", J. Chem. Society, vol. C(1), pp. 62-66 (1967).
Howson, et al., "An SAR Study for the Non-Peptide Substance P. Receptor . . . ", Biorganic & Medicinal Chemistry Letters, 2(6), pp. 559-564, (1992).
Lowe, et al., "The Discovery of Med. Chem. 35, pp. 2591-2600, (1992).
McCormick, "Properties of Periodate-Oxidised Polysaccharides, Part VII . . . ", J. Chem Society, C(23), pp. 2121-2127, (1966).
Montgomery, et al., "2-Fluropurine Ribonucleosides", J. Med. Chem., 13(3), pp. 421-427 (1970).
Payan, et al., "Substance P. Recognition by a Subset of Human T Lymphocytes", J. Clin. Invest., 74, 1532-1539 (1984).
Peyronel, et al., "Synthesis of RP-67,580, a New Potent Nonpeptide Substance P Antagonist", Biorganic and Med. Chem. Lett. 2(1), pp. 37-40, (1992).
Dorn Conrad P.
Hale Jeffrey J.
Maccoss Malcolm
Mills Sander G.
Jarvis William R. A.
Merck & Co. , Inc.
Rose David L.
Thies J. Eric
LandOfFree
Treatment of migraine with morpholine tachykinin receptor antago does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of migraine with morpholine tachykinin receptor antago, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of migraine with morpholine tachykinin receptor antago will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2077456